Juraj Bodo

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

Gaurav S. Choudhary, Sayer Al-harbi, Suparna Mazumder et al. · Cell Death and Disease · 2015 · 356 citations · Full text

Immunology, Mtor Pathways, Immunotherapy +16

The adult penile urethra is a novel entry site for HIV-1 that preferentially targets resident urethral macrophages

Yonatan Ganor, Zhicheng Zhou, Juraj Bodo et al. · Mucosal Immunology · 2012 · 89 citations · Full text

Sexual Health, Urology, Urological Research +8

Combination of ibrutinib with <scp>ABT</scp>‐199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of <scp>BTK</scp>,<scp> AKT</scp> and <scp>BCL</scp>2 pathways

Xiaoxian Zhao, Juraj Bodo, Danyu Sun et al. · British Journal of Haematology · 2014 · 88 citations · Full text

Bcl2 Family, Apoptosis, Immunology +21

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

Soledad Negrotto, Kwok Peng Ng, Anna Jankowska et al. · Leukemia · 2011 · 87 citations · Full text

Hematological Malignancy, Chromatin, Cpg Methylation Patterns +14

Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies

Isha Kapoor, Yue Li, Arishya Sharma et al. · Cell Death and Disease · 2019 · 73 citations · Full text